Figure 4. Treatment with ¹⁷⁷Lu-4A06 suppresses BC tumor growth.

A. Growth curves collected from mice bearing subcutaneous UMUC3 xenografts post treatment with vehicle or a fractionated dose of ¹⁷⁷Lu-4A06 (2 doses of 400 μCi/dose, day 0 and day 7, n = 9 mice/arm). The mean tumor volume was significantly smaller in the treated versus vehicle group by day 20 of the study. B. A Kaplan-Meier curve showing relative survival in the vehicle versus treated arms. ¹⁷⁷Lu-4A06 significantly extended survival compared to control. P < 0.01. Four of nine mice in the treated arm experienced complete tumor regressions and no regrowth was documented out to 120 days post injection. C. Mouse weight measurements from mice in the UMUC3 cohort that received vehicle of ¹⁷⁷Lu-4A06. D. Growth curves collected from mice bearing subcutaneous HT1376 xenografts post treatment with vehicle or a fractionated dose of ¹⁷⁷Lu-4A06 (2 doses of 400 μCi/dose, day 0 and day 7, n = 8 mice/arm). The mean tumor volume was significantly smaller in the treated versus vehicle group by day 10 of the study.